.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF07_Dostarlimab.Dostarlimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF07_Dostarlimab.Dostarlimab| name: | Dostarlimab |
| ATC code: | L01FF07 | route: | intravenous |
| n-compartments | 2 |
Dostarlimab is a humanized IgG4 monoclonal antibody targeting programmed death receptor-1 (PD-1). It is used as an immune checkpoint inhibitor in the treatment of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer and is approved for use in certain advanced solid tumors.
Pharmacokinetic parameters reported in adult patients with advanced solid tumors, including endometrial cancer, based on population PK analyses.
Baranda, JC, et al., & Hodi, FS (2024). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17(6) e13854–None. DOI:10.1111/cts.13854 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38898592